Filtered By:
Specialty: Infectious Diseases
This page shows you your search results in order of relevance. This is page number 9.
Order by Relevance | Date
Total 742 results found since Jan 2013.
Epstein-Barr virus protein can 'switch on' risk genes for autoimmune diseases
(NIH/National Institute of Allergy and Infectious Diseases) Infection with Epstein-Barr virus (EBV), the cause of infectious mononucleosis, has been associated with subsequent development of systemic lupus erythematosus and other chronic autoimmune illnesses, but the mechanisms behind this association were unclear. Now, a novel computational method shows that a viral protein found in EBV-infected human cells may activate genes associated with increased risk for autoimmunity. Scientists supported by the National Institute of Allergy and Infectious Diseases report their findings today in Nature Genetics.
Source: EurekAlert! - Infectious and Emerging Diseases - April 16, 2018 Category: Infectious Diseases Source Type: news
Genetically altered broadly neutralizing antibodies protect monkeys from HIV-like virus
(NIH/National Institute of Allergy and Infectious Diseases) Two genetically modified broadly neutralizing antibodies (bNAbs) protected rhesus macaques from an HIV-like virus, report scientists at the National Institute of Allergy and Infectious Diseases (NIAID). After introducing genetic mutations into two potent HIV bNAbs, researchers prepared intravenous infusions of two bNAbs. Single infusions of each modified bNAb protected monkeys against weekly exposures to simian-human immunodeficiency virus (SHIV) up to 37 weeks, compared with a median of three weeks in 12 monkeys receiving no antibody.
Source: EurekAlert! - Infectious and Emerging Diseases - April 16, 2018 Category: Infectious Diseases Source Type: news
NIAID-sponsored trial of a universal influenza vaccine begins
(NIH/National Institute of Allergy and Infectious Diseases) A Phase 2 clinical trial of an investigational universal influenza vaccine intended to protect against multiple strains of the virus has begun. The study is sponsored by the National Institute of Allergy and Infectious Diseases and is being conducted at US sites that are part of the NIAID-funded Vaccine and Treatment Evaluation Units. The trial is testing an experimental vaccine called M-001 for safety and its ability to produce potentially broad protective immune responses.
Source: EurekAlert! - Infectious and Emerging Diseases - May 4, 2018 Category: Infectious Diseases Source Type: news
NIH Trial to track outcomes of kidney transplantation from HIV+ donors to HIV+ recipients
(NIH/National Institute of Allergy and Infectious Diseases) The first large-scale clinical trial to study kidney transplantations between people with HIV has begun at clinical centers across the United States. The HOPE in Action Multicenter Kidney Study will determine the safety of this practice by evaluating kidney recipients for potential transplant-related and HIV-related complications following surgery. The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Source: EurekAlert! - Infectious and Emerging Diseases - May 7, 2018 Category: Infectious Diseases Source Type: news
Experimental MERS treatments enter clinical trial
(NIH/National Institute of Allergy and Infectious Diseases) Enrollment has begun in an early-stage clinical trial testing the safety of two human monoclonal antibodies (mAbs) designed to treat people infected with Middle East respiratory syndrome coronavirus (MERS-CoV). The trial is sponsored by the National Institute of Allergy and Infectious Diseases, part of NIH, and is funded in part by the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response, Department Health and Human Services.
Source: EurekAlert! - Infectious and Emerging Diseases - May 18, 2018 Category: Infectious Diseases Source Type: news
Early-stage respiratory syncytial virus (RSV) vaccine trial begins
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, has launched a clinical trial of an investigational vaccine designed to protect against respiratory syncytial virus (RSV). The Phase 1 study will enroll a small group of healthy adult volunteers to examine the safety of an experimental intranasal vaccine and its ability to induce an immune response. The study is being conducted at the Cincinnati Children's Hospital Medical Center.
Source: EurekAlert! - Infectious and Emerging Diseases - June 14, 2018 Category: Infectious Diseases Source Type: news
Whooping cough vaccine: The power of first impressions
(La Jolla Institute for Allergy and Immunology) In their latest study, researchers at La Jolla Institute for Allergy and Immunology (LJI) report that individuals who had been inoculated with the newer pertussis vaccine as part of their initial series of shots, mount a weaker recall response when receiving booster shots later on.
Source: EurekAlert! - Infectious and Emerging Diseases - July 9, 2018 Category: Infectious Diseases Source Type: news
Ascaris lumbricoides infection induces both, reduction and increase of asthma symptoms in a rural community.
In conclusion, in a rural tropical village, ascariasis exerts risk and protective effects on asthma symptoms, an influence associated with the severity of the infection.
PMID: 30040946 [PubMed - as supplied by publisher]
Source: Acta Tropica - July 21, 2018 Category: Infectious Diseases Authors: Zakzuk J, Casadiego S, Mercado A, Alvis-Guzman N, Caraballo L Tags: Acta Trop Source Type: research
Tickborne diseases are likely to increase, say NIAID officials
(NIH/National Institute of Allergy and Infectious Diseases) The incidence of tickborne infections in the United States has risen significantly within the past decade. It is imperative, therefore, that public health officials and scientists build a robust understanding of pathogenesis, design improved diagnostics, and develop preventive vaccines, according to a new commentary in the New England Journal of Medicine from leading scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Source: EurekAlert! - Infectious and Emerging Diseases - July 25, 2018 Category: Infectious Diseases Source Type: news
NIH study shows how MERS Coronavirus evolves to infect different species
(NIH/National Institute of Allergy and Infectious Diseases) New research published in Cell Reports from scientists at the National Institute of Allergy and Infectious Diseases (NIAID) shows how MERS-CoV can adapt to infect cells of a new species, which suggests that other coronaviruses might be able to do the same.
Source: EurekAlert! - Infectious and Emerging Diseases - August 14, 2018 Category: Infectious Diseases Source Type: news
NIH begins clinical trial of live, attenuated Zika vaccine
(NIH/National Institute of Allergy and Infectious Diseases) Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases. The NIAID-sponsored trial will enroll a total of 28 healthy, non-pregnant adults ages 18 to 50 at the Johns Hopkins Bloomberg School of Public Health Center for Immunization Research in Baltimore, and at the Vaccine Testing Center at the Larner College of Medicine at the University of Vermont.
Source: EurekAlert! - Infectious and Emerging Diseases - August 16, 2018 Category: Infectious Diseases Source Type: news
NIH officials: Closing treatment gaps critical to ending the US HIV epidemic
(NIH/National Institute of Allergy and Infectious Diseases) Daily antiretroviral therapy (ART) that suppresses HIV to levels undetectable by standard blood tests is lifesaving for individuals living with HIV and prevents sexual transmission of the virus to others. The public health community must use targeted interventions, however, to do a better job of reaching populations with low levels of viral suppression, according to experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Source: EurekAlert! - Infectious and Emerging Diseases - August 20, 2018 Category: Infectious Diseases Source Type: news
Rapid development in Central Africa increases the risk of infectious disease outbreaks
(NIH/National Institute of Allergy and Infectious Diseases) The Central Africa region is experiencing rapid urbanization, economic growth and infrastructure development. These changes, while generally positive, also make the region more vulnerable to infectious disease outbreaks. Efforts to build up the health care infrastructure in Central Africa are critically needed to mitigate or prevent a large outbreak of Ebola or other infectious disease in the region. The authors represent 12 different organizations, including the National Institute of Allergy and Infectious Diseases.
Source: EurekAlert! - Infectious and Emerging Diseases - August 22, 2018 Category: Infectious Diseases Source Type: news
HIV/AIDS research yields dividends across medical fields
(NIH/National Institute of Allergy and Infectious Diseases) Since the first cases of AIDS were reported in the United States 37 years ago, the National Institutes of Health has invested more than $69 billion in the understanding, treatment and prevention of HIV/AIDS. Beyond the development of life-saving medications and innovative prevention modalities, such research has led to numerous advances outside the HIV field, according to a new commentary from experts at NIH's National Institute of Allergy and Infectious Diseases (NIAID).
Source: EurekAlert! - Infectious and Emerging Diseases - August 28, 2018 Category: Infectious Diseases Source Type: news
Early-Stage Clinical Trial of Antimalarial Drug Begins
(NIH/National Institute of Allergy and Infectious Diseases) Enrollment has begun in a Phase 1 clinical trial to test the safety of a new investigational drug designed to treat malaria, as well as its effect on the human body. The first-in-human study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and is being conducted at the Duke University School of Medicine in Durham, North Carolina.
Source: EurekAlert! - Infectious and Emerging Diseases - September 10, 2018 Category: Infectious Diseases Source Type: news
